Evidence map›Paper›PMID 24324350›Full record

ArticleBiomarkers in cancer2013

An Antibody-based Blood Test Utilizing a Panel of Biomarkers as a New Method for Improved Breast Cancer Diagnosis.

Galit Yahalom, Daria Weiss, Ilya Novikov, Therese B Bevers, Laszlo G Radvanyi, Mei Liu, Benjamin Piura, Stefano Iacobelli, Maria T Sandri, Enrico Cassano and 5 more

3 registry-linked trialsAbstract read
In one paragraph

Article in Biomarkers in cancer, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02066025 unknown statusnot on this mapstarted 2014, after this paper: background citation

Blood Test for Breast Cancer Associated Auto Antibodies - Improvement of Octava Blood Test

TypeobservationalSponsorEventus Diagnostics LtdRan2014 to 2018Enrolled1,425ConditionsBreast Cancer
NCT02066259 unknown statusnot on this mapstarted 2014, after this paper: background citation

OctavaColon Blood Tests OctavaGold and OctavaSilver - Blood Tests for the Help in Diagnosis of Colon Cancer Clinical Study Protocol

TypeobservationalSponsorEventus Diagnostics LtdRan2014 to 2018Enrolled1,080ConditionsColon Cancer
NCT02209389 unknown statusnot on this mapstarted 2014, after this paper: background citation

OctavaPink® For Dense Breast After Negative Mammography

Typeobservational_patient_registrySponsorEventus Diagnostics LtdRan2014 to 2017Enrolled1,750ConditionsBreast CancerArmsMRI
3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Galit YahalomEventus Diagnostics (Israel) Ltd., Ora, Israel.
Daria Weiss
Ilya Novikov
Therese B Bevers
Laszlo G Radvanyi
Mei Liu
Benjamin Piura
Stefano Iacobelli
Maria T Sandri
Enrico Cassano
Tanir M Allweis
Arie Bitterman
Pnina Engelman
Luis M Vence
Marvin M Rosenberg

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In order to develop a new tool for diagnosis of breast cancer based on autoantibodies against a panel of biomarkers, a clinical trial including blood samples from 507 subjects was conducted. All subjects showed a breast abnormality on exam or breast imaging and final biopsy pathology of either breast cancer patients or healthy controls. Using an enzyme-linked immunosorbent assay, the samples were tested for autoantibodies against a predetermined number of biomarkers in various models that were used to determine a diagnosis, which was compared to the clinical status. Our new assay achieved a sensitivity of 95.2% [CI = 92.8-96.8%] at a fixed specificity of 49.5%. Receiver-operator characteristic curve analysis showed an area under the curve of 80.1% [CI = 72.6-87.6%]. These results suggest that a blood test which is based on models comprising several autoantibodies to specific biomarkers may be a new and novel tool for improving the diagnostic evaluation of breast cancer.

Indexed as

autoantibodiesbiomarkersbreast cancerdiagnostic testing

Identifiers

PMID24324350
PMCPMC3855201

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.